{"prompt": "['MC1752', '32', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Delay avelumab therapy', 'Increase frequency of monitoring to every 3 days', 'Continue and initiate supportive care per Section 9.0', 'Consider renal biopsy', 'Grade 2 to 3', 'If returns to Grade <1:', 'Creatinine increased > 1.5 and', '6 x ULN', 'Taper steroids over at least 1 month, and resume avelumab', 'therapy following steroids taper.', 'If worsens:', 'Treat as Grade 4.', 'Permanently discontinue avelumab therapy', 'Monitor creatinine daily', '1 to 2 mg/kg/day prednisone or equivalent.', 'Grade 4', 'Add prophylactic antibiotics for opportunistic infections', 'Creatinine increased > 6 x ULN', 'Consider renal biopsy', 'Nephrology consult', 'If returns to Grade 1:', 'Taper steroids over at least 1 month.', 'Cardiac disorders', 'Myocarditis', 'New onset of cardiac signs or', 'symptoms and / or new', 'laboratory cardiac biomarker', 'Permanently discontinue avelumab.', 'elevations (e.g. troponin, CK-', 'MB, BNP) or cardiac imaging', 'abnormalities suggestive of', 'myocarditis.', 'Permanently discontinue avelumab.', 'Guideline based supportive treatment as appropriate as per', 'cardiology consult.*', '1 to 2 mg/kg/day prednisone or equivalent', 'Immune-mediated myocarditis', 'Add prophylactic antibiotics for opportunistic infections.', 'Once improving, taper steroids over at least 1 month.', 'If no improvement or worsening, consider additional', 'immunosuppressants (e.g. azathioprine, cyclosporine A).', 'Respiratory, thoracic and', 'Consider delaying avelumab therapy', 'mediastinal disorders', 'Monitor for symptoms every 2 to 3 days', 'Consider Pulmonary and Infectious Disease consults', 'Pneumonitis', 'Re-assess at least every 3 weeks', 'Grade 1', 'If worsens:', 'Treat as Grade 2 or Grade 3 to 4.', 'Protocol Version Date: 21JUN2018']['MC1752', '33', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Permanently discontinue avelumab therapy.', 'Pneumonitis', 'Pulmonary and Infectious Disease consults.', 'Grade 2 or higher', 'Continue and initiate supportive care per Section 9.0', 'Endocrine Disorders', 'Continue avelumab therapy', 'Endocrinology consult if needed', 'Grade 1 endocrinopathies', '(hypothyroidism,', 'Continue and initiate supportive care per Section 9.0', 'hyperthyroidism, adrenal', 'Rule-out secondary endocrinopathies (i.e. hypopituitarism /', 'insufficiency, type I diabetes', 'hypophysitis)', 'mellitus)', 'Follow-up Management: Continue hormone', '(replacement/suppression: and monitoring of endocrine function', 'as appropriate.', 'Permanently discontinue avelumab therapy', 'For Grade 3 or 4 consider hospitalization', 'Endocrinology consult', 'Grade 2, Grade 3 or Grade 4', 'endocrinopathies', '(hypothyroidism,', 'If secondary thyroid and/or adrenal insufficiency is confirmed', 'hyperthyroidism, adrenal', '(i.e. subnormal serum FT4 with inappropriately low TSH', 'insufficiency, type I diabetes', 'and/or low serum cortisol with inappropriately low ACTH) :', 'mellitus)', 'Refer to endocrinologist for dynamic testing as indicated', 'Grade 2, Grade 3 or Grade 4', 'and measurement of other hormones (FSH, LH, GH/IGF-1,', 'hypopituitarism/Hypophysitis', 'PRL, testosterone in men, estrogens in women)', '(secondary endocrinopathies)', 'Hormone replacement/suppressive therapy as appropriate', 'Perform pituitary MRI and visual field examination as', 'indicated', 'Other Immune Related', 'Delay avelumab therapy pending clinical investigation', 'Adverse Events (irAEs) (not', 'Grade 2 or Grade 3 clinical', 'If irAE is ruled out, manage as appropriate according to the', 'described above)', 'signs or symptoms suggestive', 'diagnosis and consider re-starting avelumab therapy', 'of a potential irAE', 'If irAE is confirmed, treat as Grade 2 or 3 irAE.', 'Delay avelumab therapy', '1 to 2 mg/kg/day prednisone or equivalent', 'Add prophylactic antibiotics for opportunistic infections', 'Grade 2 irAE or first', 'Specialty consult as appropriate', 'occurrence of Grade 3 irAE', 'If improves to Grade VI 1:', 'Taper steroids over at least 1 month and resume avelumab', 'therapy following steroids taper.', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}